TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26183611
Drug: GS-5816 150
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-5816 150 mg for 3 days
Study: 26183611
Drug: GS-5816 5-150
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-5816 5-150 mg for 3 days
Study: 26183611
Drug: GS-5816 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-5816 (all doses)
Study: 15507943
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of meperidine
Study: 11675899
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg orally once daily for 12 weeks
Study: 9135352
Drug: Light halothane
Normalized name: Halothane
DrugBank: Halothane (DB01159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Light halothane anaesthesia (1% end-tidal concentration) with propofol (3 mg kg-1)
Study: 7957980
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 patch, 0.1 mg for 25 days each month (n = 7)
Study: 7957980
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 with MPA, 10 mg from days 16 to 25 each month (n = 7)
Study: 7957980
Drug: Oral equine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral equine estrogens, 1.25 mg (n = 8)
Study: 3621635
Drug: Verapamil (160-480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (160-480 mg/day)
Study: 3621635
Drug: Atenolol (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50-100 mg/day) plus Hydralazine (50-200 mg/day)
Study: 18627642
Drug: 2% dorzolamide/0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% dorzolamide/0.5% timolol fixed combination (DTFC)
Study: 16640481
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (topical anesthetic) with no distraction
Study: 1639879
Drug: Codeine syrup
Normalized name: TUSSIREX W/CODEINE SYRUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine syrup B.P. (30 mg/10 ml, q.d.s.)
Study: 1639879
Drug: Syrup vehicle
Normalized name: Base PCCA Syrup Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup vehicle (placebo)
Study: 6711556
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of maintenance therapy (n = 8)
Study: 6711556
Drug: 15 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 months of maintenance therapy (n = 13)
Study: 8071266
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (18 sessions of CBT plus desipramine withdrawn at 24 weeks)
Study: 8071266
Drug: Cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral therapy (CBT) alone (18 sessions)
Study: 2920585
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg every 12 h
Study: 2920585
Drug: Dexamethasone 1
Normalized name: dexamethasone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1 mg every 12 h
Study: 2920585
Drug: Dexamethasone 0.25
Normalized name: dexamethasone 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.25 mg every 12 h
Study: 1084093
Drug: Simultaneous vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous vaccination with BCG and measles vaccine
Study: 1084093
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine alone
Study: 1084093
Drug: Measles vaccine
Normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles vaccine alone
Study: 28502280
Drug: Custom oral
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Custom oral appliance treatment
Study: 25279818
Drug: Noribogaine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noribogaine 3 mg
Study: 25279818
Drug: Noribogaine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noribogaine 10 mg
Study: 25279818
Drug: Noribogaine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noribogaine 30 mg
Study: 24107875
Drug: Piascledine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piascledine (300 mg daily for two months, combined with artrosilene 320 mg daily for the first month)
Study: 24107875
Drug: Artrosilene (NSAIDs,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artrosilene (NSAIDs, monotherapy)
Study: 15710002
Drug: FLCA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLCA group (famotidine 20 mg b.d., lansoprazole 30 mg b.d., clarithromycin 200 mg b.d., amoxicillin 750 mg b.d. for 1 week)
Study: 15710002
Drug: LCA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCA group (lansoprazole 30 mg b.d., clarithromycin 200 mg b.d., amoxicillin 750 mg b.d. for 1 week)
Study: 9706928
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 100 microg
Study: 9706928
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intrathecal neostigmine 12.5 microg and morphine 50 microg
Study: 9706928
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride solution 0.2 mL
Study: 2118925
Drug: Peripheral parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral parenteral nutrition (PPN) for 2 weeks
Study: 28857595
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for 3.5 months
Study: 21878070
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus ethylmethylhydroxypyridine succinate
Study: 11557167
Drug: Naltrexone 0
Normalized name: MORPHINE 20MG/NALTREXONE 0.8MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 0 mg (Control)
Study: 9644751
Drug: Co-amoxiclav 625
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav 625 mg 3 times a day for 10 days
Study: 8043072
Drug: Reduction in
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in serum cholesterol concentration of 0.6 mmol/l (about 10%)
Study: 30337273
Drug: BVS857 (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: BVS857 (0.06 mg/kg intravenously once a week for 12 weeks)
Study: 27571927
Drug: Atezolizumab in
Normalized name: atezolizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab in combination with bevacizumab
Study: 27571927
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Atezolizumab + Bevacizumab)
Study: 23272986
Drug: Mindfulness therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness therapy (mindfulness‐based stress reduction and some cognitive behavioral therapy elements for BDS)
Study: 23272986
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual (2‐hour specialist medical care and brief cognitive behavioral therapy for BDS)
Study: 7577405
Drug: Amitriptyline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (25 mg for children 6-10 years and 50 mg for children 10-14 years)
Study: 7577405
Drug: Amitriptyline/Desmopressin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline/Desmopressin combination
Study: 2196771
Drug: Propranolol 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 180 or 240 mg/day
Study: 23447078
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (250 mg acipimox tablet)
Study: 23447078
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (250 mg acipimox tablet)
Study: 19301086
Drug: Rofecoxib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (50 mg, 1 h prior to incision, re-administered once daily on postoperative days 1-4)
Study: 14984373
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available herbal preparation STW 5
Study: 14984373
Drug: Research herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Research herbal preparation STW 5‐II
Study: 11317478
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg cerivastatin daily for 7 days
Study: 10726721
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg losartan/12.5 mg hydrochlorothiazide (L50H12.5C)
Study: 10726721
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg losartan monotherapy (L100)
Study: 8873542
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg of 0.75% bupivacaine with 8.25% dextrose
Study: 8873542
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg of 0.75% bupivacaine with 8.25% dextrose
Study: 8873542
Drug: 11.25 mg
Normalized name: phentermine 11.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.25 mg of 0.75% bupivacaine with 8.25% dextrose
Study: 1567188
Drug: Topical recombinant
Normalized name: thrombin topical recombinant 5000 intl units topical powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical recombinant alpha-2 interferon gel, applied four times daily for four days
Study: 1567188
Drug: Placebo, applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, applied four times daily for four days
Study: 29734823
Drug: Small-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-quantity lipid-based nutrient supplement (SQ-LNS) 20 g/d
Study: 27139495
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (CSI) - one ultrasound guided injection around the affected tendons and advice on tendon care.
Study: 27139495
Drug: Physiotherapist-administered load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapist-administered load modification and exercise intervention - education about load modification and a home-based and supervised exercise programme.
Study: 24887686
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg/d for 1 week)
Study: 24887686
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg/d for 1 week) with meloxicam
Study: 7487212
Drug: 80 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 micrograms/kg body weight recombinant human insulin-like growth factor-I (rhlGF-I)
Study: 2225606
Drug: Prostaglandin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin treatment (self-administered or given at the clinic)
Study: 2225606
Drug: Self-administered prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered prostaglandin treatment
Study: 31030606
Drug: Perindopril-indapamide treatment
Normalized name: indapamide / perindopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril-indapamide treatment
Study: 25104617
Drug: Pemetrexed maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed maintenance (500 mg/m², day 1) plus best supportive care (BSC)
Study: 20637958
Drug: FDC ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FDC ibuprofen 400 mg/paracetamol 1000 mg
Study: 20637958
Drug: FDC ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FDC ibuprofen 200 mg/paracetamol 500 mg
Study: 20637958
Drug: All FDC
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All FDC treatments
Study: 20637958
Drug: Ibuprofen 100
Normalized name: ibuprofen 100 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 100 mg/paracetamol 250 mg
Study: 20637958
Drug: Ibuprofen 200
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 mg/paracetamol 500 mg
Study: 20637958
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg/paracetamol 1000 mg
Study: 10963021
Drug: Speech and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech and language therapy (SLT) involvement
Study: 8886552
Drug: Radio-opaque markers
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radio-opaque markers (ROMs) with a test meal (451 kcal) containing a capsule with 10 ROMs, assessed after 6 hours
Study: 8886552
Drug: MRI study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MRI study with 500 ml intralipid 10% (550 kcal)
Study: 6424492
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (DSCG) 20 mg, thrice daily for 3 weeks
Study: 31987407
Drug: Palbociclib at
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib at 125 mg daily, 3 weeks on/1 week off for 2 years with endocrine therapy
Study: 21862455
Drug: Angiotensin Receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin Receptor Blockade (ARB; losartan 100 mg/day)
Study: 21862455
Drug: ARB +
Normalized name: revakinagene taroretcel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB + Diuretics (losartan 100 mg/day plus hydrochlorothiazide 25 mg/day)
Study: 21862455
Drug: LS and
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: LS and Diuretics
Study: 19291085
Drug: Daunorubicin 50
Normalized name: DAUNOrubicin 50 MG in 10 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin 50 mg/m(2)
Study: 19291085
Drug: Daunorubicin 35
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin 35 mg/m(2)
Study: 19291085
Drug: Cytarabine 200
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine 200 mg/m(2)
Study: 19291085
Drug: Cytarabine 400
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine 400 mg/m(2)
Study: 19291085
Drug: PSC‐833 (multidrug
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSC‐833 (multidrug resistance modulator)
Study: 19291085
Drug: Three courses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three courses of treatment
Study: 17975181
Drug: Risperidone 1
Normalized name: risperidone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 1 mg/d (increased to 2 mg/d after 4 weeks if needed)
Study: 9689829
Drug: T4 replacement
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4 replacement therapy in Group A (Congenital Hypothyroidism)
Study: 9689829
Drug: Long-term T4
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term T4 replacement therapy
Study: 8106768
Drug: Teicoplanin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (6 mg/kg every 24 h i.v. after initial loading every 12 h for three doses)
Study: 8106768
Drug: Vancomycin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (15 mg/kg every 12 h i.v.)
Study: 2566337
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg almitrine bismesylate
Study: 2566337
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg almitrine bismesylate
Study: 2566337
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg almitrine bismesylate
Study: 2566337
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg almitrine bismesylate
Study: 28802552
Drug: Mushroom-retained gastrostomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mushroom-retained gastrostomy (MG)
Study: 22028630
Drug: Meningococcal serogroup
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal serogroup C conjugate vaccine in 10 control villages
Study: 12584834
Drug: Composite Salvia
Normalized name: Salvia sclarea seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite Salvia Injection (CSI)
Study: 10511060
Drug: Clenoliximab (IDEC‐151),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clenoliximab (IDEC‐151), a chimeric monoclonal antibody, administered as a single intravenous infusion.
Study: 8555987
Drug: Almitrine 50
Normalized name: almitrine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine 50 mg twice a day by mouth for 60 days
Study: 1785379
Drug: Neoadjuvant cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant cyclophosphamide + doxorubicin + cisplatin (CAP) plus radiation therapy
Study: 1785379
Drug: Neoadjuvant methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant methotrexate + vinblastine + doxorubicin + cisplatin (M‐VAC) therapy
Study: 7059418
Drug: Hydrochlorothiazide plus
Normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide plus acebutolol (up to 800 mg daily)
Study: 7059418
Drug: Acebutolol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (up to 2000 mg daily)
Study: 20819550
Drug: 0.3% gatifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% gatifloxacin ophthalmic gel
Study: 20819550
Drug: 0.3% gatifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% gatifloxacin ophthalmic solution
Study: 25057270
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract EGb 761 (240 mg per day)
Study: 25057270
Drug: Betahistine (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine (32 mg per day)
Study: 21138337
Drug: Tobramycin/dexamethasone ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% (TobraDex ST) dosed 1 drop QID for 14 days
Study: 21138337
Drug: Azithromycin ophthalmic
Normalized name: azithromycin ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin ophthalmic solution 1% dosed 1 drop BID for 2 days followed by QD for 12 days
Study: 22435514
Drug: Artichoke juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artichoke juice concentrate (50 mg)
Study: 22435514
Drug: Artichoke juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artichoke juice concentrate (100 mg)
Study: 17570960
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy through Internet chat (12-15 weeks, 90 min weekly)
Study: 17894051
Drug: L-Tryptophan treatment
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-Tryptophan treatment
Study: 17894051
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment with L-Tryptophan)
Study: 31733631
Drug: LSD (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD (0.1 mg)
Study: 31733631
Drug: d-amphetamine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (40 mg)
Study: 30653847
Drug: Liraglutide (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (0.3 mg starting dose, escalating to 3.0 mg or maximum tolerated dose)
Study: 26320489
Drug: Dose-dense cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-dense cisplatin plus fluorouracil following selective radiotherapy
Study: 26320489
Drug: Dose-dense cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-dense cisplatin plus fluorouracil following selective radiotherapy (subgroup analysis)
Study: 23585663
Drug: VRS-317 (0.05,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRS-317 (0.05, 0.10, 0.20, 0.40, and 0.80 mg/kg)
Study: 23585663
Drug: VRS-317 (0.80
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRS-317 (0.80 mg/kg)
Study: 11010838
Drug: cpts-248/404 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: cpts-248/404 vaccine
Study: 26630719
Drug: Ketoprofen 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 37.5 mg
Study: 26630719
Drug: Ketoprofen 12.5
Normalized name: ketoprofen 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 12.5 mg and Ketoprofen 37.5 mg
Study: 28528211
Drug: Intravenous Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous Levetiracetam (LEV)
Study: 28528211
Drug: Intravenous Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Phenytoin (DPH)
Study: 21974796
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (50 mg.kg(‐1) in 100 ml saline over 10 min followed by a continuous infusion of 20 mg.kg.h(‐1))
Study: 11966500
Drug: Sodium monofluorophosphate
Normalized name: Sodium Monofluorophosphate
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium monofluorophosphate (150 mg) with calcium (1 g) and vitamin D (800 IU)
Study: 11966500
Drug: Calcium (1
Normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1 g) and vitamin D (800 IU) with placebo
Study: 9673745
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg (up to 80 mg daily)
Study: 9673745
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg (up to 40 mg daily +/− cholestyramine 4 g daily in 84% of cases)
Study: 2589654
Drug: 2% mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% mepivacaine (400 mg)
Study: 2589654
Drug: 1.5% etidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% etidocaine (300 mg)